Cellular Biomedicine is up 247% so far in 2015, and its market cap is $491 million. The biotechnical and medical technology investment bank, LifeTech Capital, initiated coverage of Cellular Biomedicine Group with a Strong Speculative Buy rating and a price target of $23.75, in early February. This call was quickly realized when shares eclipsed this level within only a week. However, a big driving force for this company is its cancer treatments and innovative use of stem cells.